Improving established MS therapies

How can long-term understanding of established therapies for multiple sclerosis (MS) be harnessed to improve the patient experience? Watch clips from this virtual satellite symposium to:

  • Learn about the tolerability and possibilities with intramuscular administration of peginterferon beta-1a
  • Discover new research showing how a different fumarate chemical structure can affect gastrointestinal (GI) tolerability and work productivity while maintaining bioequivalent levels of the circulating active compound mycophenolate mofetil (MMF)
  • Explore how subcutaneous (SC) administration of natalizumab can reduce the burden of treatment for patients and the healthcare system, a topic of particular relevance during the pandemic
  • Keep up to date with how long-term safety data is changing the use of established MS therapies
  • Consider new data and guidelines for MS therapies as they relate to COVID-19

Login to Medthority to view this content, or register an account.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.